The European Commission (EC) has given approval to the first PEGylated enzyme replacement therapy to treat Fabry disease.
List view / Grid view
Protalix BioTherapeutics Inc
A PEGylated enzyme replacement therapy for Fabry disease has received recommendation for a marketing authorisation from the European Medicines Agency (EMA)'s human medicines committee.
Pfizer and Protalix BioTherapeutics announce FDA approval of pediatric Indication for ELELYSO™ (taliglucerase alfa) for injection
29 August 2014 | By Pfizer
...for intravenous use for the treatment of type 1 Gaucher disease.
1 May 2012 | By Pfizer
The U.S. FDA has approved ELELYSO™...